结晶
过程开发
产量(工程)
过程(计算)
化学
组合化学
化学工程
反应条件
分子
粒径
材料科学
有机化学
工艺优化
工艺工程
工艺设计
晶体生长
化学合成
活性成分
一步到位
过程分析技术
设计质量
分离过程
作者
Yasuhiro Nagato,Yasutaka Baba,Muneo Shoji,Yuko Suzumura,Noriyuki Nakajima
标识
DOI:10.1021/acs.oprd.5c00167
摘要
The novel LpxC inhibitor T-1228 is a candidate drug molecule for multidrug-resistant Gram-negative bacterial infection. We developed a process chemistry route to T-1228. The final step of T-1228 drug substance synthesis consists of a deprotection reaction under acidic conditions and a crystallization process incorporating polymorph control. The process parameters of the deprotection reaction were optimized through a Design of Experiments (DoE) study to limit the formation of a critical impurity. The production method established for the crystallization process was developed by means of process analytical technology (PAT): it controls the quality and particle size of the drug substance and selectively yields only the desired crystal polymorph. By applying the newly developed process chemistry route, we have successfully manufactured T-1228 at 24% total yield from commercially available 1,3-diethyl 2-bromo-2-methylpropanedioate.
科研通智能强力驱动
Strongly Powered by AbleSci AI